Starton Therapeutics Receives Clinical Trial Authorization in Europe to Initiate Phase I Clinical Trial of STAR-LLD Continuous Delivery Lenalidomide

Starton Therapeutics, Inc. announced that it has received its first Clinical Trial Authorization in the Netherlands to initiate a Phase I study evaluating STAR-LLD, a continuous delivery lenalidomide in development to expand the standard of care for the most common blood cancers, multiple myeloma and chronic lymphocytic leukemia, bioavailability in human subjects.